Clinical Trial Update: 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder [Phase 1]

View source ↗

Summary

Phase 1 crossover study assessing safety and tolerability of SB-121 (Lactobacillus reuteri with Sephadex and maltose) in adolescents and young adults with autis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autistic Disorder

Drugs mentioned

• SB-121 (Lactobacillus reuteri with Sephadex and maltose)

Snippet

Sponsor: Scioto Biosciences, Inc. | Conditions: Autistic Disorder | Phase 1 | Status: COMPLETED | Results posted: 2024-03-25